{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:05:50Z","timestamp":1773389150466,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA215651"],"award-info":[{"award-number":["CA215651"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA252707"],"award-info":[{"award-number":["CA252707"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL151334"],"award-info":[{"award-number":["HL151334"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.isci.2021.102931","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T02:27:45Z","timestamp":1627612065000},"page":"102931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The BTK\/PI3K\/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Dhananjaya","family":"Pal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6366-6112","authenticated-orcid":false,"given":"Kendra R.","family":"Vann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6123-8499","authenticated-orcid":false,"given":"Namood E.","family":"Sahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo A.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-8283","authenticated-orcid":false,"given":"Dalia","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana G.","family":"Kutateladze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald L.","family":"Durden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2021.102931_bib1","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1073\/pnas.1613091114","article-title":"Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis","volume":"114","author":"Andrews","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.isci.2021.102931_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-020-0181-z","article-title":"A triple action CDK4\/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity","volume":"6","author":"Burgoyne","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.isci.2021.102931_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2021.102931_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2021.102931_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.isci.2021.102931_bib6","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.isci.2021.102931_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.isci.2021.102931_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00197809","article-title":"NMRPipe: a multidimensional spectral processing system based on UNIX pipes","volume":"6","author":"Delaglio","year":"1995","journal-title":"J.\u00a0Biomol. NMR"},{"key":"10.1016\/j.isci.2021.102931_bib9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.isci.2021.102931_bib10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.isci.2021.102931_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.283.5400.393","article-title":"Impaired B cell development and\u00a0proliferation in absence of phosphoinositide 3-kinase p85alpha","volume":"283","author":"Fruman","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.isci.2021.102931_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41467-020-14604-6","article-title":"A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2021.102931_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis,\u00a0pathogenesis, prognostication, and\u00a0management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2021.102931_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle\u00a0cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2021.102931_bib15","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.isci.2021.102931_bib16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/annonc\/mdw672","article-title":"Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer","volume":"28","author":"Matulonis","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2021.102931_bib17","doi-asserted-by":"crossref","first-page":"25332","DOI":"10.18632\/oncotarget.25011","article-title":"The B cell receptor signaling pathway in mantle cell lymphoma","volume":"9","author":"Merolle","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2021.102931_bib18","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.isci.2021.102931_bib19","unstructured":"Morales, G.A., Garlich, J.R., and Durden, D.L. (2020). Single molecule compounds providing multi-target inhibition of btk and other proteins and methods of use thereof. Patent number WO2020023340A1."},{"key":"10.1016\/j.isci.2021.102931_bib20","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2021.102931_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13543784.2020.1760245","article-title":"Novel agents for mantle cell lymphoma: molecular rational and clinical data","volume":"29","author":"Sarkozy","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.isci.2021.102931_bib22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2021.102931_bib23","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1038\/s41598-020-68964-6","article-title":"Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets","volume":"10","author":"Vann","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2021.102931_bib24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-Mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2021.102931_bib25","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat. Commun."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004221008993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004221008993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:52:35Z","timestamp":1762879955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004221008993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2589004221008993"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2021.102931","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The BTK\/PI3K\/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2021.102931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021","name":"copyright","label":"Copyright"}],"article-number":"102931"}}